Neoplasms

3,817 trials 1,526 recruiting

Filter these 3,817 trials by phase, country and sponsor.

Open in Search →

H1-antihistaminE treatment in combiNation with immunotHerapy in pAtieNts with advanced non small cell lung canCEr: A single- center phase -E… Recruiting

2024-518633-28-00 Advanced non small lung cancer 4 2022-10-13
A research study to evaluate the safety and effectiveness of Zilovertamab Vedotin with or without Nemtabrutinib in adults with B-cell Malign… Recruiting

2022-501374-19-00 Aggressive and Indolent B-cell Malignancies (mantle cel 4 2022-09-16
First in human study of BAY2927088 in participants who have advanced non-small cell lung cancer (NSCLC) with mutations in the genes of epide… Recruiting

2023-503795-24-00 Avanced Non-Small Cell Lung Cancer 7 2022-09-16
A Study of Abemaciclib (LY2835219) with Abiraterone in Men with Prostate Cancer that has Spread to Other Parts of the Body and is Expected t… Recruiting

2022-500461-28-06 High-Risk Metastatic Hormone-Sensitive Prostate Cancer 5 2022-09-15
Evaluation of Niraparib alone compared to the combination of Niraparib and Bevacizumab in patients receiving chemotherapy for newly diagnose… Recruiting

2024-516066-11-00 Patients with newly diagnosed, histologically confirmed 5 2022-08-31
A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab. Recruiting

2024-513185-19-00 Extensive stage small cell lung cancer (ES-SCLC) 9 2022-07-13
The SEAMARK Study: Phase 2 Study of First-line Encorafenib and Cetuximab Plus Pembrolizumab in Participants With BRAF V600E-mutant,MSIH/dMMR… Recruiting

2024-512119-34-00 MSI-H/dMMR metastatic colorectal cancer 4 2022-06-20
Study Evaluating the Safety, Efficacy, and Pharmacokinetics of Mosunetuzumab and a Combined Regimen of Mosunetuzumab and Venetoclax in Patie… Recruiting

2022-501876-24-00 Relapsed or Refractory (R/R) Chronic Lymphocytic Leukem 3 2022-06-17
IMPALA Protocol: Intrapleural Photodynamic Therapy by Video-Assisted Thoracoscopy Followed by Anti-PD-1 NIVOLUMAB in Patients With Malignant… Recruiting

2024-514103-33-00 malignant pleural mesothelioma 4 2022-05-09
Comparison of Standard Dose Alectinib to Alectinib in Adjusted Dose Based on Alectinib Bloodlevels (ADAPT ALEC) Recruiting

2023-506886-76-00 ALK positive non-small cell lung cancer 6 2022-03-23
A Study to Assess Disease Activity and Adverse Events of Intravenous (IV) Telisotuzumab Vedotin Compared to IV Docetaxel in Adult Participan… Recruiting

2023-505749-14-00 c-Met overexpressing EGFR wildtype non-squamous non-sma 5 2022-03-20
A phase II study evaluating the efficacy of Selective Internal Radiation Therapy combined with Capecitabine in the neoadjuvant setting of Op… Recruiting

2024-516683-29-00 Biliary tract cancer 4 2022-02-04
Study to evaluate the efficacy and safety of supportive mitomycin C administered via electric current in the treatment of non-muscle invasiv… Recruiting

2024-520006-19-00 Non-muscle invasive bladder cancer 6 2021-12-15
A Study Evaluating the Safety, Pharmacokinetics, and Efficacy of Alectinib in Pediatric Participants With ALK Fusion-Positive Solid or CNS T… Recruiting

2023-504084-17-00 ALK fusion-positive extracranial solid or primary CNS t 9 2021-07-12
A Phase 1/2 Study of Bleximenib in Participants with Acute Leukemia Recruiting

2023-506581-31-00 Acute Leukemia 1 2021-06-15
A Phase 1, Open-Label, Safety and Tolerability Study of INCB057643 in Participants With Myelofibrosis and Other Advanced Myeloid Neoplasms Recruiting

2023-506145-38-00 Treatment of participants with MF, MDS, ET, or MDS/MPN 3 2021-05-11
Study of Tislelizumab and/or Pamiparib Containing Treatments in Participants With Advanced Malignancies Recruiting

2023-508883-31-00 Solid tumors and hamatological malignancies 5 2021-02-23
An unblinded, multi-center study evaluating long-term treatment with Zanubrutinib (BGB-3111) regimens in patients with blood cancer in the l… Recruiting

2024-511267-28-00 B-cell malignancies 5 2021-02-17
LIBRETTO-432: A Placebo-controlled Double-Blinded Randomized Phase 3 Study of Adjuvant Selpercatinib in RET fusion-Positive NSCLC Recruiting

2023-506784-33-00 RET fusion-Positive NSCLC 5 2021-01-19
A clinical study of different treatments for kidney cancer (MK-3475-03A) Recruiting

2023-506838-68-00 Renal cell carcinoma 9 2020-12-10
A Phase 2, Open-Label, Multicenter, Rollover Study to Provide Continued Treatment for Participants Previously Enrolled in Studies of Parsacl… Recruiting

2022-501687-18-00 Advanced malignancies and IAI diseases 4 2020-10-28
A study to test the effect of chemotherapy before surgery compared to surgery alone in patients with high risk retroperitoneal sarcoma. Recruiting

2023-505261-84-00 Primary high risk leiomyosarcoma or liposarcoma of retr 5 2020-10-06
Long-Term Follow-Up (LTFU) of Participants Treated with Adoptive Cell Therapies Recruiting

2024-513033-21-00 Non-small cell lung cancer (NSCLC) 3 2020-09-14
A Phase 1/2 First in Human Study of the Menin-MLL (KMT2A) Inhibitor KO-539 in Patients with Relapsed or Refractory Acute Myeloid Leukemia Recruiting

2023-510509-17-00 Relapsed and/or refractory Acute Myeloid Leukemia 7 2020-06-17